Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.

The analyst notes that Amneal has moved its generics business from simple oral tablets to more complex products, which should support long-term growth. This shift, successful new product launches ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and ...

Amneal launched mesalamine 800 mg delayed-release tablets for moderately active ulcerative colitis in adults. These approvals highlight Amneal's expanding portfolio, robust R&D capabilities ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a strategy that has led to a 45% increase in its ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...

Amneal Pharma ((AMRX)) has held its Q4 earnings call. Read on for the main highlights of the call. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and ...

Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...